Lazela

Ranolazine, the active ingredient in Lazela, is an antianginal agent presented as an oral tablet for systemic use. It reduces myocardial oxygen demand and improves exercise tolerance in patients with chronic stable angina, helping to relieve chest pain associated with reduced coronary blood flow.

GNH USA supplies Lazela as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory‑aligned distribution for this cardiovascular therapy. The company ensures quality compliance with EU standards and supports global healthcare providers with timely delivery.

Lazela (ranolazine) is used in the management of ischemic heart disease, specifically chronic angina syndromes.

- Chronic stable angina: reduces the frequency of angina attacks and improves exercise capacity. - Angina pectoris: alleviates chest‑pain episodes during physical exertion. - Refractory angina: provides symptom relief when conventional anti‑anginal therapies are insufficient.

Ranolazine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Nausea - Constipation - Headache - Fatigue - Palpitations

Serious or Rare Side Effects: - Prolonged QT interval - Severe arrhythmias - Hepatotoxicity - Hypotension (rare) - Syncope - Stevens‑Johnson syndrome

When prescribing Lazela, clinicians should consider several safety measures and patient‑specific factors.

- Assess cardiac history: evaluate for existing QT prolongation or arrhythmias. - Review concomitant medications: avoid drugs that also prolong QT interval. - Monitor liver function: periodic tests recommended during long‑term therapy. - Adjust dose in renal impairment: consider reduced dosing in severe renal dysfunction. - Counsel patients on symptoms: advise to report palpitations, fainting, or severe dizziness promptly. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Ranolazine interacts with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase ranolazine plasma levels. - Strong CYP2D6 inhibitors (e.g., quinidine, paroxetine): can raise ranolazine concentrations and risk toxicity. - Other QT‑prolonging agents (e.g., sotalol, amiodarone): combined use may exacerbate cardiac repolarization delay.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Digoxin: ranolazine can increase digoxin levels; monitor serum concentrations. - Anticoagulants (e.g., warfarin): may require INR monitoring due to potential interaction.